The Food and Drug Administration granted Fast Track designation to Conatus Pharmaceuticals Inc.'s (Nasdaq: CNAT) emricasan development program to treat liver cirrhosis caused by nonalcoholic steatohepatitis. The stock price leaped 36 cents to close at $1.96.
Conatus Pharmaceuticals granted Fast Track designation
February 03, 2016 at 17:54 PM EST
